OS Therapies (NYSEAMERICAN:OSTX) Posts Quarterly Earnings Results

OS Therapies (NYSEAMERICAN:OSTX) announced its quarterly earnings data on Friday. The company reported ($0.20) EPS for the quarter, FiscalAI reports.

OS Therapies Stock Up 1.3%

OSTX traded up $0.02 on Friday, reaching $1.62. The company’s stock had a trading volume of 401,092 shares, compared to its average volume of 644,429. The company has a market capitalization of $73.77 million, a price-to-earnings ratio of -1.50 and a beta of -0.73. OS Therapies has a fifty-two week low of $1.15 and a fifty-two week high of $2.57. The stock has a 50 day moving average of $1.68 and a two-hundred day moving average of $1.57.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Susquehanna International Group LLP acquired a new stake in OS Therapies during the 3rd quarter worth $29,000. Mercer Global Advisors Inc. ADV purchased a new stake in OS Therapies in the third quarter valued at $40,000. Bridgeway Capital Management LLC acquired a new position in OS Therapies in the second quarter valued at $47,000. Jane Street Group LLC acquired a new position in OS Therapies in the fourth quarter valued at $39,000. Finally, XTX Topco Ltd purchased a new position in shares of OS Therapies during the second quarter worth about $63,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on OSTX shares. D. Boral Capital reiterated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a research note on Thursday, April 30th. Roth Capital initiated coverage on shares of OS Therapies in a report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price objective on the stock. Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 4th. Finally, Lake Street Capital lowered their target price on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, OS Therapies currently has an average rating of “Moderate Buy” and an average target price of $13.33.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.